vadimezan Report issue

Small molecule Experimental
AACT DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Vadimezan is a tumor-vascular disrupting agent (tumor-VDA) that attacks the blood supply of a cancerous tumor to cause tumor regression.   Wikipedia

Chemistry

  • SMILES: Cc1ccc2c(=O)c3cccc(CC(=O)O)c3oc2c1C
  • InChIKey: XGOYIMQSIKSOBS-UHFFFAOYSA-N
  • Mol. Mass: 282.3
  • ALogP: 3.19
  • ChEMBL Molecule:
    vadimezan  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

5,6-dimethyl-9-oxo-9h-xanthene-4-acetic acid | 5,6-dimethylxanthenone-4-acetic acid | 5,6-dimethyl xanthenone acetic acid | 5,6-dimethylxanthenoneacetic acid | 5,6-dimethylxanthenoneacetic acid, sodium salt | 5,6-mexaa | as1404 | asa404 | asa 404 | asa-404 | dimethyloxoxanthene acetic acid | dmxaa | nsc 640488 | vadimezan

Organizations (15)

Research & Development (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (6)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (6)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Transitional Cell (Phase 2)

Lung Neoplasms (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Prostatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 18
  • # of Trial Organizations: 15

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue